It is plausible that LAPTM4B-NRF2 signaling is modulated differentially in different cell lines with distinct mutational, genetic and epigenetic profiles; being more activated in KRAS mutant compared to wild type lung cancer cells. The gene discussed is LAPTM4B; the disease is lung carcinoma.